金河生物(002688.SZ)擬向動物藥業增資3500萬元
格隆匯11月15日丨金河生物(002688.SZ)公佈,為滿足公司經營發展的需要,公司擬以自有資金3500萬元人民幣向公司全資子公司內蒙古金河動物藥業有限公司(“動物藥業”)進行增資。此次增資完成後,動物藥業的註冊資本增至人民幣5000萬元,公司持有其股權比例仍為100%。
內蒙古金河動物藥業有限公司經營範圍:許可經營項目:無 一般經營項目:預混劑、殺蟲劑(液體)、粉劑、飼料添加劑生產銷售,動保教育培訓諮詢服務、動保互聯網信息服務,銷售獸用化學藥品、中藥製劑、生化藥品、外用殺蟲劑、消毒劑、原料藥、中藥材(中藥飲片)。(依法須經批准的項目,經相關部門批准後方可開展經營活動)
此次對動物藥業公司增資,主要是為了提高其註冊資金以適應市場化銷售對競標企業註冊資金的要求,同時也有利於增加動物藥業公司的資本金,便於未來業務的拓展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.